TARGUT BIOTECHNOLOGIES INC.

Biotech · Private

Gut-targeted phosphodiesterase-5 inhibitor analogs (polar sildenafil derivatives) for colorectal cancer chemoprevention

Grants
$192K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Colon cancer prevention with non-systemic PDE5 inhibitors$191,738
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1244QX Therapeutics, Inc.——
1245DIGITAL PROTEOMICS LLC——
1246New England Discovery Partners, LLC——
1247TARGUT BIOTECHNOLOGIES INC.——
1248SignalRx Pharmaceuticals Inc.—$250K
1249Tooth Bank, LLC—$200K
1250EnLiven Therapeutics—$140M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.